Laurantis Pharma Oy and Ark Therapeutics Sign Manufacturing Agreement for Production of Lymfactin™ Investigational Treatment for Breast Cancer-Associated Lymphedema
10/15/2012 9:07:15 AM
More...
|
Laurantis Pharma Oy Issued Patent for Cis-UCA as a Treatment for Bladder Cancer
10/9/2012 9:53:10 AM
More...
|
Laurantis Pharma Oy Completes Funding Round for Research Program
9/4/2012 9:18:01 AM
More...
|
U.S. Patent Office Allows Laurantis Pharma Oy Application for Treatment of Skin Inflammation
8/1/2012 8:46:28 AM
More...
|
Laurantis Pharma Oy Release: Investigational Cis-urocanic Acid Eye Drops for Dry Eye Syndrome Well Tolerated, in Phase 1 Clinical Study
6/28/2012 9:23:51 AM
More...
|
Laurantis Pharma Oy Release: Research Team Discovers Four-Fold Improvement in Ability to Restore Lymphatic Function With Adenovirally-Delivered VEGF-C Gene Therapy After Lymph Node Transplant Surgery Compared to the Surgery Alone
3/7/2012 8:44:43 AM
More...
|
Laurantis Pharma Oy Release: New Treatment for Lymphedema Could Mean Breakthrough for Breast Cancer Patients
9/22/2011 12:07:06 PM
More...
|